Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Myriad Genetics (MYGN)

Myriad Genetics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MYGN
DateTimeSourceHeadlineSymbolCompany
23/05/202423:00GlobeNewswire Inc.Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual MeetingNASDAQ:MYGNMyriad Genetics Inc
16/05/202421:05GlobeNewswire Inc.New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate CancerNASDAQ:MYGNMyriad Genetics Inc
15/05/202422:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MYGNMyriad Genetics Inc
15/05/202422:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MYGNMyriad Genetics Inc
15/05/202421:24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MYGNMyriad Genetics Inc
14/05/202421:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MYGNMyriad Genetics Inc
13/05/202421:24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MYGNMyriad Genetics Inc
13/05/202417:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MYGNMyriad Genetics Inc
08/05/202413:23IH Market NewsReddit Rises 15% After First Quarterly Report, Upstart and Twilio Plunge Due to Weak Q2 Forecast, and More in EarningsNASDAQ:MYGNMyriad Genetics Inc
08/05/202413:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MYGNMyriad Genetics Inc
07/05/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MYGNMyriad Genetics Inc
07/05/202421:05GlobeNewswire Inc.Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDANASDAQ:MYGNMyriad Genetics Inc
07/05/202414:00GlobeNewswire Inc.Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict BusinessNASDAQ:MYGNMyriad Genetics Inc
30/04/202421:05GlobeNewswire Inc.Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024NASDAQ:MYGNMyriad Genetics Inc
17/04/202413:00GlobeNewswire Inc.Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health MonitorNASDAQ:MYGNMyriad Genetics Inc
16/04/202414:15GlobeNewswire Inc.New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal ScreenNASDAQ:MYGNMyriad Genetics Inc
09/04/202413:00GlobeNewswire Inc.Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight TestingNASDAQ:MYGNMyriad Genetics Inc
22/03/202401:40GlobeNewswire Inc.Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority DateNASDAQ:MYGNMyriad Genetics Inc
20/03/202420:05GlobeNewswire Inc.Myriad Genetics Announces Patent Granted for SneakPeek® Snap DeviceNASDAQ:MYGNMyriad Genetics Inc
04/03/202421:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MYGNMyriad Genetics Inc
28/02/202413:31Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MYGNMyriad Genetics Inc
27/02/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MYGNMyriad Genetics Inc
27/02/202421:05GlobeNewswire Inc.Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the FoNASDAQ:MYGNMyriad Genetics Inc
27/02/202414:15GlobeNewswire Inc.Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3NASDAQ:MYGNMyriad Genetics Inc
26/02/202421:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MYGNMyriad Genetics Inc
26/02/202421:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MYGNMyriad Genetics Inc
21/02/202421:05GlobeNewswire Inc.Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024NASDAQ:MYGNMyriad Genetics Inc
15/02/202421:05GlobeNewswire Inc.Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s HealthNASDAQ:MYGNMyriad Genetics Inc
14/02/202421:47Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MYGNMyriad Genetics Inc
14/02/202413:24Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MYGNMyriad Genetics Inc
 Showing the most relevant articles for your search:NASDAQ:MYGN